| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,619,000 |
| Market
Cap: |
587.05(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.26 - $19.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 993 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Travere Therapeutics is a biopharmaceutical company focused on identifying, developing and delivering therapies to people living with kidney, liver, and metabolic diseases. Co.'s approved products include: Thiola and Thiola EC (tiopronin), which are approved for the treatment of cystinuria, a genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones; and Cholbam (cholic acid capsules), which is approved for the treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisome biogenesis disorder-Zellweger spectrum disorder.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
54 |
59,539 |
71,172 |
110,112 |
| Total Sell Value |
$364 |
$522,023 |
$673,181 |
$1,525,239 |
| Total People Sold |
1 |
7 |
7 |
7 |
| Total Sell Transactions |
1 |
16 |
21 |
43 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reed Elizabeth E |
SVP, GC & Corporate Secretary |
• – – |
2023-09-05 |
4 |
AS |
$14.71 |
$26,699 |
D/D |
(1,815) |
58,096 |
|
-33% |
|
| Rote William E. |
Senior Vice President, R&D |
• – – |
2023-09-05 |
4 |
AS |
$14.71 |
$26,699 |
D/D |
(1,815) |
61,173 |
|
-33% |
|
| Dube Eric M |
Chief Executive Officer |
• • – |
2023-09-05 |
4 |
AS |
$14.71 |
$65,533 |
D/D |
(4,455) |
242,595 |
|
-33% |
|
| Reed Elizabeth E |
SVP, GC & Corporate Secretary |
• – – |
2023-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
59,911 |
|
- |
|
| Rote William E. |
Senior Vice President, R&D |
• – – |
2023-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,300 |
62,988 |
|
- |
|
| Dube Eric M |
Chief Executive Officer |
• • – |
2023-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,900 |
247,050 |
|
- |
|
| Meckler Jeffrey A |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
74,500 |
|
- |
|
| Baynes Roy D. |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
24,500 |
|
- |
|
| Squarer Ron |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
22,375 |
|
- |
|
| Orwin John A |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
22,375 |
|
- |
|
| Poole Sandra |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
17,000 |
|
- |
|
| Bruhn Suzanne Louise |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
15,750 |
|
- |
|
| Lyons Gary A |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
44,500 |
|
- |
|
| Brinkley Ruth W |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
12,750 |
|
- |
|
| Coughlin Timothy P |
Director |
– • – |
2023-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
42,500 |
|
- |
|
| Calvin Sandra |
SVP, Chief Accounting Officer |
• – – |
2023-05-11 |
4 |
AS |
$16.12 |
$1,967 |
D/D |
(122) |
42,247 |
|
-20% |
|
| Cline Christopher R. |
Chief Financial Officer |
• – – |
2023-05-10 |
4 |
S |
$16.59 |
$7,548 |
D/D |
(455) |
51,031 |
|
19% |
|
| Calvin Sandra |
SVP, Chief Accounting Officer |
• – – |
2023-05-10 |
4 |
AS |
$16.59 |
$7,233 |
D/D |
(436) |
42,369 |
|
-19% |
|
| Reed Elizabeth E |
SVP, GC & Corporate Secretary |
• – – |
2023-05-10 |
4 |
AS |
$16.59 |
$13,687 |
D/D |
(825) |
56,611 |
|
-19% |
|
| Rote William E. |
Senior Vice President, R&D |
• – – |
2023-05-10 |
4 |
AS |
$16.59 |
$13,687 |
D/D |
(825) |
59,211 |
|
-19% |
|
| Cline Christopher R. |
Chief Financial Officer |
• – – |
2023-04-11 |
4 |
S |
$21.49 |
$1,010 |
D/D |
(47) |
51,486 |
|
35% |
|
| Calvin Sandra |
SVP, Chief Accounting Officer |
• – – |
2023-02-02 |
4 |
AS |
$22.42 |
$8,071 |
D/D |
(360) |
42,805 |
|
-23% |
|
| Cline Christopher R. |
Chief Financial Officer |
• – – |
2023-02-01 |
4 |
S |
$21.75 |
$34,542 |
D/D |
(1,588) |
51,533 |
|
22% |
|
| Heerma Peter |
Chief Commercial Officer |
• – – |
2023-02-01 |
4 |
S |
$21.75 |
$38,697 |
D/D |
(1,779) |
82,069 |
|
22% |
|
| Rote William E. |
Senior Vice President, R&D |
• – – |
2023-02-01 |
4 |
AS |
$22.25 |
$57,628 |
D/D |
(2,590) |
60,036 |
|
-22% |
|
455 Records found
|
|
Page 2 of 19 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.36 (5.68%) 
